Apr 19 |
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Apr 19 |
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
|
Apr 18 |
Bio-Path announces $1.2M registered direct offering priced at-the-market
|
Apr 18 |
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Apr 18 |
Bio-Path shares rally after clinical trial progress of BP1002
|
Apr 18 |
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
|
Apr 15 |
Bio-Path gets newly issued patents in Mexico, Australia and Japan
|
Apr 15 |
Bio-Path Holdings Expands Global Patent Portfolio
|
Mar 27 |
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
|
Mar 10 |
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript
|